OncoMatch/Clinical Trials/NCT05887492
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Is NCT05887492 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including TNG260 and Pembrolizumab for non small cell lung cancer.
Treatment: TNG260 · Pembrolizumab — The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: STK11 mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function/reserve per local labs
Kidney function
adequate renal function per local labs
Liver function
adequate liver function per local labs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA Hematology/Oncology · Santa Monica, California
- SCRI at HealthOne · Denver, Colorado
- Florida Cancer Specialists · Sarasota, Florida
- Dana Farber Cancer Institute · Boston, Massachusetts
- Henry Ford Health System · Detroit, Michigan
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify